The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > LATEST
LATEST
-
BUSINESS Daiichi Sankyo Rolls Out Lung, Breast Cancer Data for HER3-Directed ADC
March 22, 2023
-
BUSINESS Mitsubishi Tanabe Files Canaglu OD Tablet Form in Japan
March 22, 2023
-
BUSINESS Xtandi Plus Leuprolide Meet PIII Goal in Non-Metastatic Prostate Cancer: Astellas
March 20, 2023
-
REGULATORY Oral Abortion Pill Mefeego Up for Another Round of Panel Reviews on March 24
March 20, 2023
-
REGULATORY Expert Panel Discusses 2% Buffer Zone, Member Floats “Regional Index”
March 20, 2023
-
REGULATORY Expert Panel Seeks Revision of Drug Pricing Rules to Stabilize Supplies
March 20, 2023
-
REGULATORY Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
March 20, 2023
-
COMMENTARY Revision of Guidelines on Drone Drug Deliveries Expected by March-End: Will Powerful Meds Be OK'ed?
March 17, 2023
-
BUSINESS Takeda Updates Qdenga Peak Sales Estimate to US$1.6-2 Billion
March 17, 2023
-
REGULATORY 97 Health Damages Reported for Kymriah in Japan: April-September
March 17, 2023
-
BUSINESS Fujifilm to Make Foray into Drug Discovery CRO Business
March 17, 2023
-
BUSINESS Twymeeg No 1 in GP Promotion in January, Dayvigo Most Pitched for HP: Intage
March 17, 2023
-
REGULATORY Japan to Add Purchased Doses of Paxlovid, Xocova to Govt Stockpile
March 17, 2023
-
REGULATORY Health Minister Vows to Make Use of Govt-Purchased Xocova
March 17, 2023
-
BUSINESS CSL R&D Head Touts Cost-Effectiveness of Hemophilia Gene Therapy Hemgenix
March 17, 2023
-
BUSINESS Illumina Eyes Japan Launch of Comprehensive Genomic Profiling Test This Year
March 16, 2023
-
BUSINESS Paxlovid to Enter Normal Distribution from March 22: Pfizer Japan
March 16, 2023
-
BUSINESS Ono, PeptiDream in Deal for Macrocyclic Constrained Peptide Therapeutics
March 16, 2023
-
REGULATORY Japan Damage Relief Panel Recognizes 11 More Deaths Possibly Tied to COVID Jabs
March 16, 2023
-
BUSINESS Iron Solution MonoVer Now Available in Japan; Donepezil Patch, Cresemba to Hit Market in April
March 16, 2023
ページ
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…